Laboratorio Reig Jofre, S.A.

Equities

RJF

ES0165359029

Pharmaceuticals

Market Closed - BME 11:35:26 2024-04-26 am EDT 5-day change 1st Jan Change
2.58 EUR +2.38% Intraday chart for Laboratorio Reig Jofre, S.A. +1.98% +14.67%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Laboratorio Reig Jofre, S.A., 2023 Earnings Call, Mar 13, 2024
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Spain’s Reig Jofre Names New CFO MT
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Transcript : Laboratorio Reig Jofre, S.A., Q4 2022 Earnings Call, Mar 07, 2023
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Why Europe's drug shortages may get worse RE
Reig Jofre JV Inks Deal with Indian Pharmaceutical to Commercialize Biosimilar Medicine MT
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Laboratorio Reig Jofre, S.A.(BME:RJF) dropped from S&P Global BMI Index CI
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Laboratorio Reig Jofre, S.A.’s Equity Buyback announced on July 18, 2019 has Expired. The company has repurchased 74,107 shares, representing 0.1% for €0.26 million. CI
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Laboratorio Reig Jofre, S.A.(BME:RJF) added to S&P Global BMI Index CI
Laboratorio Reig Jofre S A : Reig Jofre Delays Manufacturing of Johnson & Johnson's COVID-19 Vaccine to H2 MT
Tranche Update on Laboratorio Reig Jofre, S.A.'s Equity Buyback Plan announced on July 22, 2019. CI
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Laboratorio Reig Jofre S A : Reig Jofre Snaps Up Entire British Unit to Bolster UK Presence MT
Laboratorio Reig Jofre, S.A. acquired remaining 49% stake in Reig Jofre UK Ltd from FIEX managed by Compañía Española de Financiación del Desarrollo, COFIDES, S.A, S.M.E. CI
Tranche Update on Laboratorio Reig Jofre, S.A.'s Equity Buyback Plan announced on July 22, 2019. CI
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Laboratorio Reig Jofre S A : Spain's Reig Jofre to Start Producing Johnson & Johnson's COVID-19 Vaccine in Q2 MT
Laboratorio Reig Jofre S A : Reif Jofre Launches Polish Unit MT
Chart Laboratorio Reig Jofre, S.A.
More charts
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. RJF Stock
  4. News Laboratorio Reig Jofre, S.A.
  5. Laboratorio Reig Jofre S A : Spain's Reig Jofre to Start Producing Johnson & Johnson's COVID-19 Vaccine in Q2